{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=106",
    "query": {
      "condition": "Multi Center",
      "page": 106
    },
    "page_size": 10
  },
  "pagination": {
    "page": 106,
    "page_size": 10,
    "total_count": 6602,
    "total_pages": 661,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=107&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multi+Center&page=105&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T00:57:22.870Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02268851",
      "title": "A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "TGR-1202",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2014-11",
      "completion_date": "2022-10",
      "has_results": true,
      "last_update_posted_date": "2024-11-15",
      "last_synced_at": "2026-11-12T00:57:22.870Z",
      "location_count": 5,
      "location_summary": "Monterey, California • Hartford, Connecticut • Brewer, Maine + 1 more",
      "locations": [
        {
          "city": "Monterey",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Brewer",
          "state": "Maine"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02268851"
    },
    {
      "nct_id": "NCT00612872",
      "title": "Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Parkinson Disease",
        "Alzheimer Disease",
        "Healthy Controls",
        "Multiple Sclerosis"
      ],
      "interventions": [
        {
          "name": "[123I]CLINDE",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Institute for Neurodegenerative Disorders",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "30 Years to 50 Years"
      },
      "enrollment_count": 46,
      "start_date": "2008-01",
      "completion_date": "2009-11-01",
      "has_results": false,
      "last_update_posted_date": "2019-04-03",
      "last_synced_at": "2026-11-12T00:57:22.870Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00612872"
    },
    {
      "nct_id": "NCT05608005",
      "title": "Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Influenza",
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Panblok + MF59 Dose 1",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Panblok + MF59 Dose 2",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Unadjuvanted Panblok Dose 3",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sanofi Pasteur, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 581,
      "start_date": "2022-11-03",
      "completion_date": "2024-02-13",
      "has_results": true,
      "last_update_posted_date": "2025-09-24",
      "last_synced_at": "2026-11-12T00:57:22.870Z",
      "location_count": 16,
      "location_summary": "Mesa, Arizona • Hallandale, Florida • Hollywood, Florida + 11 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Hallandale",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Saint Augustine",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05608005"
    },
    {
      "nct_id": "NCT00809094",
      "title": "NAC Phase IIB: A Multi-Center, Phase IIB, Randomized, Placebo-controlled, Double-Blind Study Of The Effects Of N-Acetylcysteine On Redox Changes and Lung Inflammation In Cystic Fibrosis Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine (NAC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "7 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "7 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2008-11",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2013-04-22",
      "last_synced_at": "2026-11-12T00:57:22.870Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Stanford, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00809094"
    },
    {
      "nct_id": "NCT03938246",
      "title": "Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)"
      ],
      "interventions": [
        {
          "name": "TVB-2640 25 mg (US)",
          "type": "DRUG"
        },
        {
          "name": "TVB-2640 50 mg (US)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (US)",
          "type": "DRUG"
        },
        {
          "name": "TVB-2640 50 mg (China)",
          "type": "DRUG"
        },
        {
          "name": "Placebo (China)",
          "type": "DRUG"
        },
        {
          "name": "TVB-2640 75 mg (US)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sagimet Biosciences Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 142,
      "start_date": "2019-03-22",
      "completion_date": "2021-10-02",
      "has_results": true,
      "last_update_posted_date": "2024-12-19",
      "last_synced_at": "2026-11-12T00:57:22.870Z",
      "location_count": 12,
      "location_summary": "Chula Vista, California • Montclair, California • Sacramento, California + 9 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Montclair",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Miami Lakes",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03938246"
    },
    {
      "nct_id": "NCT00691873",
      "title": "Study to Evaluate the Effect of Xolair(Omalizumab) on Improving the Tolerability of Specific Immunotherapy in Patients With at Least Moderate Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Xolair",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Mississippi Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 14,
      "start_date": "2006-05",
      "completion_date": "2007-10",
      "has_results": false,
      "last_update_posted_date": "2008-06-06",
      "last_synced_at": "2026-11-12T00:57:22.870Z",
      "location_count": 1,
      "location_summary": "Jackson, Mississippi",
      "locations": [
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00691873"
    },
    {
      "nct_id": "NCT03522441",
      "title": "Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acne Vulgaris"
      ],
      "interventions": [
        {
          "name": "Clindamycin 1% Gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Akorn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "12 Years to 40 Years"
      },
      "enrollment_count": 1125,
      "start_date": "2018-04-27",
      "completion_date": "2019-04-22",
      "has_results": true,
      "last_update_posted_date": "2020-10-05",
      "last_synced_at": "2026-11-12T00:57:22.870Z",
      "location_count": 10,
      "location_summary": "Encino, California • Sherman Oaks, California • Brandon, Florida + 4 more",
      "locations": [
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        },
        {
          "city": "Brandon",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        },
        {
          "city": "Miramar",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03522441"
    },
    {
      "nct_id": "NCT05417594",
      "title": "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Malignancies"
      ],
      "interventions": [
        {
          "name": "AZD9574",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide (TMZ)",
          "type": "DRUG"
        },
        {
          "name": "[11C]AZ1419 3391",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab Deruxtecan (T-DXd)",
          "type": "DRUG"
        },
        {
          "name": "Datopotamab Deruxtecan (Dato-DXd)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 695,
      "start_date": "2022-06-24",
      "completion_date": "2028-02-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-12T00:57:22.870Z",
      "location_count": 11,
      "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 7 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05417594"
    },
    {
      "nct_id": "NCT04268953",
      "title": "Study to Compare the Pharmacokinetics of Daily Administration of Tricaprilin on Ketone Body Production",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Tricaprilin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cerecin",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2020-02-27",
      "completion_date": "2020-05-01",
      "has_results": false,
      "last_update_posted_date": "2020-07-08",
      "last_synced_at": "2026-11-12T00:57:22.870Z",
      "location_count": 1,
      "location_summary": "Tempe, Arizona",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04268953"
    },
    {
      "nct_id": "NCT01256294",
      "title": "Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Renal Transplant"
      ],
      "interventions": [
        {
          "name": "Generic Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Branded Tacrolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 71,
      "start_date": "2010-10",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2012-06-21",
      "last_synced_at": "2026-11-12T00:57:22.870Z",
      "location_count": 2,
      "location_summary": "Cincinnati, Ohio • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01256294"
    }
  ]
}